Nantahala Discloses 1,109-Share Stake in Cellectar (CLRB) — 0.06%
Cellectar Biosciences, Inc. (CLRB) disclosure shows that Nantahala Capital Management, LLC and two individuals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,109 shares of the company’s common stock, representing 0.06% of the class.
Rhea-AI Filing Summary
Cellectar Biosciences, Inc. (CLRB) disclosure shows that Nantahala Capital Management, LLC and two individuals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,109 shares of the company’s common stock, representing 0.06% of the class. The shares are held by funds and separately managed accounts under Nantahala's control and the Reporting Persons report shared voting and dispositive power over those 1,109 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.
Positive
- Disclosure of ownership by an investment adviser provides transparency to the market
- Position is small (1,109 shares; 0.06%), indicating no controlling intent
- Certifies holdings are in the ordinary course of business, not acquired to influence control
Negative
- None.
Insights
TL;DR Nantahala reports a small, non-controlling stake of 1,109 shares (0.06%) held across funds and accounts.
The position size is immaterial to company control or near-term market impact. Shared voting and dispositive power indicates the stake is managed at the adviser/fund level rather than held outright by a single individual. This is a routine disclosure under Schedule 13G, consistent with ownership "in the ordinary course of business." No changes to capital structure, financing, or operating metrics are disclosed.
TL;DR Reporting shows non-control ownership and affirms no intent to influence management or control.
The filing classifies the reporting persons as an investment adviser and control persons for purposes of reporting beneficial ownership of the same assets. The statement that the securities were not acquired to influence control is a standard certification for Schedule 13G filings. Given the 0.06% stake and shared powers, this disclosure does not indicate governance changes or proxy implications.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was the CLRB position acquired to influence company control?
Which individuals are named as reporting persons alongside Nantahala Capital?
What classification is Nantahala Capital under the Schedule 13G filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.